Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

Anaplastic lymphoma kinase (ALK) gene fusions occur in 3%–7% of non-small-cell lung cancer (NSCLC) cases. Ceritinib, a once-daily, oral ALK inhibitor, has activity against crizotinib-resistant and crizotinib-naïve NSCLC, including brain metastases. Ceritinib (Zykadia™) was granted accelerated approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaefer, Eric S, Baik, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818057/
https://www.ncbi.nlm.nih.gov/pubmed/27069372
http://dx.doi.org/10.2147/CMAR.S96471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818057/
https://www.ncbi.nlm.nih.gov/pubmed/27069372
http://dx.doi.org/10.2147/CMAR.S96471

Ejemplares similares